EMVision (ASX:EMV) receives AU$5M grant, shares gain 5%

May 18, 2022 01:48 AM PDT | By Bhawna Gupta

EMVision (ASX:EMV) receives AU$5M grant, shares gain 5% — Image source: © Robeo | Megapixl.com

EMVision gets Modern Manufacturing Initiative Grant

EMVision has received a Modern Manufacturing Initiative (MMI) grant from the Department of Industry, Science, Energy, and Resources.

The company will get an AU$5 million in non-dilutive cash funding through the MMI Manufacturing Translation Stream initiative.

This programme provides money to enterprises to help them fund initiatives, implement new technology, and enhance industrial processes. The grant, according to EMVision, is a matched funding programme that is subject to documentation and requirements being agreed upon.

EMVision has not supplied any information about how the funds would be used. The details will be announced later, according to management.

Stock performance: Although the share price of EMVision increased today, it has been on a downward trend. The shares have fallen more than 30% in the last one year.

Source: © Haak78 | Megapixl.com

About EMVision

EMVision Medical Devices Limited focuses on medical imaging technology research and commercialisation. The company is working on creating and commercialising portable medical imaging equipment that uses electromagnetic microwave imaging to diagnose and monitor strokes and other medical conditions.

EMVision’s recent development

EMVision announced recently that it had signed a strategic original equipment manufacturer (OEM) agreement with Keysight Technologies Australia Pty Ltd.

In radiofrequency (RF) test and measurement technology, Keysight is the world leader. Customers of Keysight come from various industries, including 5G/6G, aerospace, defence, automotive, and now healthcare.

Data Source- Company announcement dated 04 May 2022

EMVision and Keysight formed a strategic partnership in April 2019 to develop the specialised healthcare focused VNA solutions that are the focus of this agreement. The 12-month VNA volume commitment is to provide VNA units for planned clinical trials. The agreement is for a 12-month term and can be renewed if both parties agree before it expires.

Also Read: EMVision (ASX:EMV) signs A$8M funding deal with Australian Stroke Alliance

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.